Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for shares of Adaptimmune Therapeutics in a research report issued on Tuesday, March 25th. Zacks Small Cap analyst M. Kim forecasts that the biotechnology company will earn ($0.23) per share for the quarter. The consensus estimate for Adaptimmune Therapeutics' current full-year earnings is ($0.14) per share. Zacks Small Cap also issued estimates for Adaptimmune Therapeutics' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.11) EPS.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The firm had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million.
Other equities research analysts have also recently issued research reports about the company. Scotiabank decreased their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a report on Friday, March 21st. StockNews.com assumed coverage on Adaptimmune Therapeutics in a research note on Saturday. They issued a "buy" rating on the stock. Wells Fargo & Company dropped their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research note on Friday, March 21st. Finally, Guggenheim decreased their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Adaptimmune Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $1.93.
Check Out Our Latest Research Report on ADAP
Adaptimmune Therapeutics Trading Down 2.4 %
Shares of ADAP traded down $0.01 on Thursday, hitting $0.20. 1,148,930 shares of the stock traded hands, compared to its average volume of 1,718,868. Adaptimmune Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.55. The stock's 50 day moving average is $0.51 and its two-hundred day moving average is $0.66. The firm has a market capitalization of $51.43 million, a P/E ratio of -0.91 and a beta of 2.52. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62.
Institutional Trading of Adaptimmune Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. raised its stake in shares of Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 28,526 shares during the period. Two Sigma Advisers LP raised its position in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 58,787 shares during the period. Two Sigma Investments LP lifted its stake in shares of Adaptimmune Therapeutics by 33.5% during the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC boosted its position in shares of Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after buying an additional 21,688 shares during the period. Finally, LPL Financial LLC grew its stake in shares of Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock valued at $99,000 after buying an additional 94,623 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company's stock.
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Read More
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
